JTC Employer Solutions Trustee Ltd Sells 429,725 Shares of Haleon PLC Sponsored ADR $HLN

Posted by Brenda Bartman on May 29th, 2026

JTC Employer Solutions Trustee Ltd lowered its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN – Free Report) by 60.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 282,504 shares of the company’s stock after selling 429,725 shares during the period. JTC Employer Solutions Trustee Ltd’s holdings in Haleon were worth $2,860,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in HLN. Bank of America Corp DE grew its position in shares of Haleon by 116.7% during the second quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock worth $128,423,000 after purchasing an additional 6,669,923 shares in the last quarter. Optiver Holding B.V. purchased a new stake in shares of Haleon during the third quarter worth about $45,593,000. JPMorgan Chase & Co. grew its position in shares of Haleon by 36.6% during the third quarter. JPMorgan Chase & Co. now owns 11,984,672 shares of the company’s stock worth $107,503,000 after purchasing an additional 3,207,986 shares in the last quarter. ABC Arbitrage SA grew its position in shares of Haleon by 159.4% during the third quarter. ABC Arbitrage SA now owns 2,727,350 shares of the company’s stock worth $24,464,000 after purchasing an additional 1,675,889 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its position in shares of Haleon by 3,548.4% during the second quarter. BNP Paribas Financial Markets now owns 1,684,968 shares of the company’s stock worth $17,473,000 after purchasing an additional 1,638,784 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

HLN has been the subject of several research analyst reports. Argus upgraded Haleon to a “strong-buy” rating in a research report on Tuesday, March 17th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Finally, Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.

Check Out Our Latest Report on HLN

Haleon Price Performance

Shares of Haleon stock opened at $9.22 on Friday. The stock has a market cap of $40.90 billion, a price-to-earnings ratio of 23.65, a price-to-earnings-growth ratio of 2.12 and a beta of 0.15. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.71 and a current ratio of 0.92. The stock has a 50 day moving average price of $9.56 and a 200-day moving average price of $9.97. Haleon PLC Sponsored ADR has a one year low of $8.71 and a one year high of $11.42.

Haleon (NYSE:HLN – Get Free Report) last announced its earnings results on Saturday, February 14th. The company reported $6.32 EPS for the quarter. The company had revenue of $3.65 billion during the quarter. Equities analysts expect that Haleon PLC Sponsored ADR will post 0.56 EPS for the current year.

Haleon Profile

(Free Report)

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.